Cagent Vascular Hires Paul Wilson as Chief Commercial Officer

Paul Wilson has joined Cagent Vascular Inc. as chief commercial officer (CCO) to lead the company’s commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His role also entails helping Cagent Vascular expand awareness, accelerate growth, and strengthen the market positioning of its proprietary serration balloon technology.

“Paul is an exceptional leader with a deep understanding of our industry and a strong vision for growth,” Cagent Vascular Chairman/CEO Brian Walsh stated. “As we continue to expand our presence and bring solutions to market, his expertise and leadership will be invaluable to driving our commercial success. His track record in commercial execution and strategic expansion of disruptive Peripheral technology aligns perfectly with our mission.”

Wilson has many years of medical device industry experience, having held senior commercial leadership positions at Teleflex and Abbott. With a proven track record of driving revenue growth, expanding market share, and fostering strategic partnerships, he will play a critical role in scaling Cagent Vascular’s commercial footprint, according to company executives.

“I am thrilled to join Cagent Vascular at such an exciting time in its growth journey,” Wilson said. “The company has developed a truly innovative solution that addresses a critical need in vascular care. I look forward to working with this team to support the continued success of serration technology in clinical practice.”

Cagent Vascular’s proprietary serration balloon technology is designed to optimize vessel preparation, enhance arterial expansion, and address challenging lesion morphologies in peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI).

The Serranator and Serranator SL-PRO PTA Serration Balloon Catheters are U.S. Food and Drug Administration-cleared, novel balloons using stainless steel micro-serration technology, designed to create linear, interrupted scoring along the endoluminal surface. With 1,000 times more point force compared with conventional balloon angioplasty, serration occurs during slow-and-low balloon inflation and is designed to aid arterial expansion, effectively achieving luminal gain in all lesion morphologies with minimal recoil.

Founded and led by serial medical technology entrepreneurs, Cagent Vascular developed Serration Technology to treat peripheral artery disease—an improvement to conventional angioplasty, the most commonly performed procedure to restore blood flow. Although angioplasty has been used clinically for more than 50 years, there are still significant opportunities to optimize the therapy and to improve cardiovascular disease treatment.